EPIT Stock Overview
A biomedical company, develops and commercializes ingestible therapeutic devices worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Epitomee Medical Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪11.36 |
| 52 Week High | ₪15.70 |
| 52 Week Low | ₪2.49 |
| Beta | 0.87 |
| 1 Month Change | 23.60% |
| 3 Month Change | 11.59% |
| 1 Year Change | 191.06% |
| 3 Year Change | -64.98% |
| 5 Year Change | n/a |
| Change since IPO | -72.25% |
Recent News & Updates
Statutory Profit Doesn't Reflect How Good Epitomee Medical's (TLV:EPIT) Earnings Are
Nov 20
Here's Why We're Not Too Worried About Epitomee Medical's (TLV:EPIT) Cash Burn Situation
Oct 15Recent updates
Statutory Profit Doesn't Reflect How Good Epitomee Medical's (TLV:EPIT) Earnings Are
Nov 20Here's Why We're Not Too Worried About Epitomee Medical's (TLV:EPIT) Cash Burn Situation
Oct 15We Like These Underlying Return On Capital Trends At Epitomee Medical (TLV:EPIT)
Aug 18We Think Epitomee Medical (TLV:EPIT) Can Afford To Drive Business Growth
Jun 26Shareholder Returns
| EPIT | IL Medical Equipment | IL Market | |
|---|---|---|---|
| 7D | 25.5% | -1.4% | -0.5% |
| 1Y | 191.1% | 19.0% | 23.0% |
Return vs Industry: EPIT exceeded the IL Medical Equipment industry which returned 19% over the past year.
Return vs Market: EPIT exceeded the IL Market which returned 23% over the past year.
Price Volatility
| EPIT volatility | |
|---|---|
| EPIT Average Weekly Movement | 12.1% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: EPIT's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: EPIT's weekly volatility has decreased from 25% to 12% over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 42 | Dan Hashimshony | www.epitomeemedical.com |
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. Its capsule is used for weight management, waist circumference reduction, and cardiovascular risk factors reduction. Epitomee Medical Ltd has a strategic partnership with Nestlé Health Science S.A. for the development and commercialization of the weight loss capsule.
Epitomee Medical Ltd Fundamentals Summary
| EPIT fundamental statistics | |
|---|---|
| Market cap | ₪335.93m |
| Earnings (TTM) | ₪9.72m |
| Revenue (TTM) | ₪36.47m |
34.6x
P/E Ratio9.2x
P/S RatioIs EPIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPIT income statement (TTM) | |
|---|---|
| Revenue | US$10.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.00m |
| Other Expenses | US$7.34m |
| Earnings | US$2.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.09 |
| Gross Margin | 100.00% |
| Net Profit Margin | 26.64% |
| Debt/Equity Ratio | 0% |
How did EPIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 11:31 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Epitomee Medical Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|